On October 7, ZAI LAB fell 5.82% in regular trading to HK$19.53, with turnover of HK$2.3588 million, giving back part of the prior session's 5.4% gain.

The decline followed broad sector weakness, with Cansino Biologics down 6.16%, Harbour BioMed down 6.08%, Innovent Biologics down 1.96%, BeiGene down 1.81%, and Akeso down 1.63%. The move came as profit-taking set in after an ESMO-related surge the previous day, when the company had gained 5.4% amid optimism over Chinese innovators' growing presence at the 2026 ESMO Late-Breaking Abstracts.

Adding to pressure, disclosure records showed The Goldman Sachs Group, Inc. cut its long position in ZAI LAB to 4.94% from 5.01%, while JPMorgan earlier reduced its stake to 10.7% via an off-market sale at HK$20.5723 per share. Despite positive pipeline catalysts around the DLL3 ADC ZL-1310 and a global Phase III trial in first-line small cell lung cancer, short-term sentiment has cooled.

ZAI LAB is a biopharmaceutical company focused on oncology, immunology, neuroscience, and infectious diseases, with assets including Zejula, Optune, Qinlock, NuZYRA, and VYVGART across China and overseas markets.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)